Corcept Therapeutics高管于2025年12月1日出售了520万美元股票，盈利略有偏差。 Corcept Therapeutics executives sold $5.2M in stock on Dec. 1, 2025, amid slightly miss earnings.

2025年12月1日,Corphy治疗机构内部人士Joseph Douglas Leon、Sean Maduck和CEOJoseph Belanoff共出售65 000股,里昂和马达克各出售5 000股和20 000股,贝兰霍夫出售40 000股,每股约79.50美元。 On December 1, 2025, Corcept Therapeutics insiders Joseph Douglas Lyon, Sean Maduck, and CEO Joseph Belanoff sold a combined 65,000 shares, with Lyon and Maduck each selling 5,000 and 20,000 shares respectively, and Belanoff selling 40,000 shares, all at around $79.50 per share. 向证交会申报了销售情况,大大减少了它们的股份。 The sales were filed with the SEC, reducing their stakes significantly. 该公司报告第三季度收入为0.16 EPS,略低于估计数,收入为2.0764亿美元,比上一年增长13.8%。 The company reported third-quarter earnings of $0.16 EPS, slightly below estimates, with revenue of $207.64 million, up 13.8% year-over-year. 股票以8367美元关闭,市场上限为88 000亿美元,并获得一致的“稳住”评级。 The stock closed at $83.67, with a market cap of $8.80 billion and a consensus "Hold" rating.